


Product Name : BML-277
Cat. No. : PC-49284
CAS No. : 516480-79-8
Molecular Formula : C₂₀H₁₄ClN₃O₂
Molecular Weight : 363.80
Target : Checkpoint Kinase (Chk)
Solubility : 10 mM in DMSO



Biological Activity

BML-277 (BML277) is a potent, selective and ATP-competitive inhibitor of **Chk2** serine/threonine kinase with IC₅₀ of 15 nM, >1000-fold selectivity over Chk1 and Cdk1/B kinases.

BML-277 dose dependently protects human CD4+ and CD8+ T-cells from apoptosis due to ionizing radiation.

BML-277 specifically inhibit CHK2 phosphorylation at Thr68 at different time course, but not CHK1 phosphorylation.

BML-277 significantly promoted pneumonia symptoms, including mortality, lung infiltration of immune cells, and the abundance of lung pro-inflammatory cytokines in vivo.

BML-277 reduced protein poly(ADP-ribosyl)ation (PARylation), FANCD2 monoubiquitination, homologous recombination and OR CRC cell growth in vitro and in vivo.

References

Kristen L Arienti, et al. *J Med Chem*. 2005 Mar 24;48(6):1873-85.

Xie F, et al. *Exp Lung Res*. 2022 Jan 25:1-8.

Hsieh CC, et al. *Br J Cancer*. 2022 Aug 23. doi: 10.1038/s41416-022-01946-9.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com